Disc Medicine Unveils Initial RALLY-MF Phase 2 Data for Anemia in Myelofibrosis at ASH 2025
Reuters
Nov 03, 2025
<a href="https://laohu8.com/S/IRON">Disc Medicine</a> Unveils Initial RALLY-MF Phase 2 Data for Anemia in Myelofibrosis at ASH 2025
Disc Medicine Inc. announced the upcoming presentation of initial data from its RALLY-MF Phase 2 trial evaluating DISC-0974 for the treatment of anemia in patients with myelofibrosis. The data will be presented at the 67th American Society of Hematology $(ASH)$ Annual Meeting, scheduled for December 6-9, 2025, in Orlando, FL. The company will highlight results from the ongoing study, including use of DISC-0974 as both monotherapy and in combination with JAK inhibitor therapies such as ruxolitinib and momelotinib. Additionally, Disc Medicine will present a poster on the design of a Phase 2 trial of DISC-3405 in polycythemia vera and notes that initial readouts for this and a Phase 1b trial of DISC-3405 in sickle cell disease are expected in 2026. The abstracts are available on the ASH conference website, with new data to be disclosed at the meeting.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9566585-en) on November 03, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.